SI1051159T1 - Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis - Google Patents

Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis

Info

Publication number
SI1051159T1
SI1051159T1 SI9830205T SI9830205T SI1051159T1 SI 1051159 T1 SI1051159 T1 SI 1051159T1 SI 9830205 T SI9830205 T SI 9830205T SI 9830205 T SI9830205 T SI 9830205T SI 1051159 T1 SI1051159 T1 SI 1051159T1
Authority
SI
Slovenia
Prior art keywords
leishmaniasis
treatment
oral administration
solid pharmaceutical
compositions containing
Prior art date
Application number
SI9830205T
Other languages
English (en)
Slovenian (sl)
Inventor
J�Rgen Engel
Werner Sarlikiotis
Thomas Klenner
Peter Hilgard
Dieter Sauerbier
Eckhard Milsmann
Original Assignee
Zentaris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Ag filed Critical Zentaris Ag
Publication of SI1051159T1 publication Critical patent/SI1051159T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI9830205T 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis SI1051159T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/000345 WO1999037289A1 (en) 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis

Publications (1)

Publication Number Publication Date
SI1051159T1 true SI1051159T1 (en) 2002-10-31

Family

ID=8166843

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9830205T SI1051159T1 (en) 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis

Country Status (24)

Country Link
US (1) US6544551B1 (zh)
EP (1) EP1051159B1 (zh)
JP (1) JP2002501015A (zh)
KR (1) KR100517399B1 (zh)
CN (1) CN100413492C (zh)
AT (1) ATE215817T1 (zh)
AU (1) AU756805B2 (zh)
BR (1) BR9814772A (zh)
CA (1) CA2318260C (zh)
CZ (1) CZ299229B6 (zh)
DE (1) DE69804865T2 (zh)
DK (1) DK1051159T3 (zh)
ES (1) ES2175663T3 (zh)
HU (1) HUP0004363A3 (zh)
IL (1) IL136196A (zh)
NO (1) NO20003674L (zh)
NZ (1) NZ505648A (zh)
PL (1) PL189654B1 (zh)
PT (1) PT1051159E (zh)
SI (1) SI1051159T1 (zh)
SK (1) SK284839B6 (zh)
TR (1) TR200001717T2 (zh)
UA (1) UA68372C2 (zh)
WO (1) WO1999037289A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
DE10203195A1 (de) * 2002-01-25 2003-08-07 Zentaris Ag Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
WO2003090757A1 (en) * 2002-04-26 2003-11-06 Rudolf Perl Pharmaceutical compositions of phospholipid derivatives
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
PT1545553E (pt) 2002-07-30 2011-09-12 Aeterna Zentaris Gmbh Utilização de alquilfosfocolinas em combinação com medicamentos antitumorais
PL1663197T3 (pl) 2003-09-09 2008-09-30 Biogen Idec Int Gmbh Zastosowanie pochodnych kwasu fumarowego do leczenia niewydolności serca oraz astmy
DE202005022112U1 (de) 2004-10-08 2014-04-24 Forward Pharma A/S Pharmazeutische Zusammensetzungen mit kontrollierter Freisetzung, umfassend einen Fumarsaureester
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
WO2010020276A1 (en) * 2008-08-19 2010-02-25 Orphanidis Pharma Research Gmbh Treatment of coccidian parasites
CA2794513A1 (en) 2010-03-31 2011-10-06 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer
US9358244B2 (en) 2010-11-22 2016-06-07 Oblita Therapeutics Bvba Solid dosage forms of oleyl phosphocholine
EP3616701A1 (en) 2011-06-24 2020-03-04 GRI Bio, Inc. Prevention and treatment of inflammatory conditions
WO2014166941A1 (en) * 2013-04-08 2014-10-16 Academisch Medisch Centrum Miltefosin or perifosin for use in the treatment of ibd
KR102193599B1 (ko) 2014-09-17 2020-12-21 스티어라이프 인디아 프라이빗 리미티드 발포성 조성물 및 이의 제조방법
CN104473941A (zh) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 一种含有米替福新的药物制剂及其制备方法
WO2017098481A1 (en) 2015-12-12 2017-06-15 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
EP3965739B1 (en) * 2019-04-12 2024-07-10 Oblita Therapeutics BVBA Tablet dosage formulations of oleyl phosphocholine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE888444C (de) * 1951-11-10 1953-08-31 Benckiser Gmbh Joh A Verfahren zum Tablettieren von hygroskopischen Praeparaten
CA1280369C (en) * 1985-12-04 1991-02-19 Hansjorg Eibl Pharmaceutical with anti-tumor effect
US4762658A (en) * 1986-10-08 1988-08-09 Central Soya Company, Inc. Method of tableting of de-oiled phosphatides (lecithin)
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
EP0916343A1 (de) * 1989-09-27 1999-05-19 ASTA Medica Aktiengesellschaft Verwendung von Alkylphosphorsäure-Verbindungen zur Bekämpfung von Psoriasis-Erkrankungen
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis

Also Published As

Publication number Publication date
NO20003674D0 (no) 2000-07-18
IL136196A0 (en) 2001-05-20
NO20003674L (no) 2000-07-18
KR100517399B1 (ko) 2005-09-28
PL189654B1 (pl) 2005-09-30
US6544551B1 (en) 2003-04-08
HUP0004363A3 (en) 2002-12-28
CZ20002596A3 (cs) 2000-10-11
ES2175663T3 (es) 2002-11-16
SK284839B6 (sk) 2005-12-01
CA2318260A1 (en) 1999-07-29
DE69804865D1 (de) 2002-05-16
JP2002501015A (ja) 2002-01-15
CN1283111A (zh) 2001-02-07
HUP0004363A2 (hu) 2001-04-28
TR200001717T2 (tr) 2000-11-21
EP1051159B1 (en) 2002-04-10
AU756805B2 (en) 2003-01-23
AU6212198A (en) 1999-08-09
DK1051159T3 (da) 2002-08-05
UA68372C2 (en) 2004-08-16
ATE215817T1 (de) 2002-04-15
DE69804865T2 (de) 2002-11-07
IL136196A (en) 2004-07-25
PL342838A1 (en) 2001-07-16
CN100413492C (zh) 2008-08-27
WO1999037289A1 (en) 1999-07-29
KR20010034311A (ko) 2001-04-25
BR9814772A (pt) 2000-10-24
PT1051159E (pt) 2002-09-30
EP1051159A1 (en) 2000-11-15
CA2318260C (en) 2006-11-21
SK9862000A3 (en) 2000-11-07
NZ505648A (en) 2002-10-25
CZ299229B6 (cs) 2008-05-21

Similar Documents

Publication Publication Date Title
PL342838A1 (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
EP1049459A4 (en) ORAL LIQUID COMPOSITIONS
AP2001002062A0 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake.
BG104727A (en) Pharmaceutical composition of topiramate
PL334566A1 (en) Treatment of sclerosis multiplex by oral and inhalatory administration of a copolymer-1
MXPA01004547A (es) Administracion oral de analogos de adenosina.
BG105564A (en) Galantamine-containing composition with controlled release
HUP0101281A3 (en) Diphenyl-piperidine butanamides as glycine transport inhibitors, process for producing them, use of them for producing medicaments and the pharmaceutical compositions containing them
MXPA03010549A (es) Formas de dosificacion de oxcarbazepina.
BG105173A (en) Novel salt form of pantoprazole
BG105292A (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
JO2663B1 (en) Abandronate is a large dose
IL139320A0 (en) Pharmaceutical compositions containing human parathyroid hormone
UA66856C2 (uk) Тієнопіримідини, спосіб їх одержання, фармацевтична композиція та спосіб її одержання
MY119090A (en) Synthetic polysaccharides, process for their preparation and pharmaceutical compositions containing them
NZ320355A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6- tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
CA2344686A1 (en) High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
AU2003271811A8 (en) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same
IL111805A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
BG104673A (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
BG104424A (en) Pseudopolymorphic forms of 2-[2-[4-[bis(4-fluorophenyl) methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride
UA32939A (uk) Сульфокамфокаїн, спосіб його виготовлення і спосіб підготовки обладнання для виготовлення сульфокамфокаїну
EP0817643A4 (en) COMPOUNDS AND COMPOSITIONS FOR PROVIDING ACTIVE AGENTS
UA30798A (uk) Спосіб пролонгованої терапії онкологічних хворих